Velindre Library
@vcclibrary.bsky.social
Velindre University NHS Trust Library, the only cancer specialist library service in Wales. Supporting NHS and academic staff, students and health professionals.
Pre-Christmas stress? Let's just sit down for a bit and listen to Immunobuddies... Episode 172: Clinical Application of the Microbiome Final Part with International Expert Professor Monty Pal City of Hope California @velindrecc.bsky.social @rickyfrazer1.bsky.social open.spotify.com/episode/2ql2...
Episode 172: Clinical Application of the Microbiome Final Part with International Expert Professor Monty Pal City of Hope California
open.spotify.com
December 12, 2025 at 9:40 AM
Pre-Christmas stress? Let's just sit down for a bit and listen to Immunobuddies... Episode 172: Clinical Application of the Microbiome Final Part with International Expert Professor Monty Pal City of Hope California @velindrecc.bsky.social @rickyfrazer1.bsky.social open.spotify.com/episode/2ql2...
Education and training in cardio-oncology for the noncardiologist: current disparities and a proposal for the future. @velindrecc.bsky.social @rickyfrazer1.bsky.social journals.lww.com/jcardiooncol...
journals.lww.com
December 11, 2025 at 2:18 PM
Education and training in cardio-oncology for the noncardiologist: current disparities and a proposal for the future. @velindrecc.bsky.social @rickyfrazer1.bsky.social journals.lww.com/jcardiooncol...
Specialist Neurology Involvement and Impact in Immune Checkpoint Inhibitor-Related Neurotoxicity: Experience in a Unified Healthcare System. @velindrecc.bsky.social @rickyfrazer1.bsky.social www.mdpi.com/2072-6694/17...
www.mdpi.com
December 11, 2025 at 2:16 PM
Specialist Neurology Involvement and Impact in Immune Checkpoint Inhibitor-Related Neurotoxicity: Experience in a Unified Healthcare System. @velindrecc.bsky.social @rickyfrazer1.bsky.social www.mdpi.com/2072-6694/17...
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. @velindrecc.bsky.social www.ejcancer.com/article/S095...
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study
Immune checkpoint inhibitor (ICI) combinations have improved outcomes in patients
with advanced melanoma; however, long term survival remains poor. The addition of
therapeutic cancer vaccines to ICI c...
www.ejcancer.com
December 11, 2025 at 2:10 PM
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. @velindrecc.bsky.social www.ejcancer.com/article/S095...
NICE Technology Appraisal Guideline [TA1116]: Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. www.nice.org.uk/guidance/ta1...
Overview | Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia | Guidance | NICE
www.nice.org.uk
December 11, 2025 at 1:59 PM
NICE Technology Appraisal Guideline [TA1116]: Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. www.nice.org.uk/guidance/ta1...
Effects of different intensity of resistance exercise on shoulder function and immune function in young and middle-aged postoperative #BreastCancer patients: a randomized control trial. link.springer.com/article/10.1...
Effects of different intensity of resistance exercise on shoulder function and immune function in young and middle-aged postoperative breast cancer patients: a randomized control trial - Supportive Ca...
Purpose This study aimed to investigate the effects of different intensities of resistance exercise on shoulder function and immune response in young and middle-aged breast cancer patients after surge...
link.springer.com
December 11, 2025 at 1:57 PM
Effects of different intensity of resistance exercise on shoulder function and immune function in young and middle-aged postoperative #BreastCancer patients: a randomized control trial. link.springer.com/article/10.1...
Trastuzumab Deruxtecan in Residual HER2-Positive Early #BreastCancer [Phase 3, open-label, international, randomized trial]. www.nejm.org/doi/full/10....
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer | NEJM
Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer and residual disease after neoadjuvant therapy are at high risk for recurrence. In a phase 3, open-label, ...
www.nejm.org
December 11, 2025 at 1:51 PM
Trastuzumab Deruxtecan in Residual HER2-Positive Early #BreastCancer [Phase 3, open-label, international, randomized trial]. www.nejm.org/doi/full/10....
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative #BreastCancer: the ImmunoBreast phase Ib clinical trial. jitc.bmj.com/content/13/1...
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib cl...
Background Adoptive cell transfer-based immunotherapy holds promise for treating advanced cancer. However, a key challenge remains: generating sufficient numbers of lymphocytes capable of recognizing ...
jitc.bmj.com
December 11, 2025 at 1:44 PM
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative #BreastCancer: the ImmunoBreast phase Ib clinical trial. jitc.bmj.com/content/13/1...
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
December 11, 2025 at 1:06 PM
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ascopubs.org/doi/10.1200/...
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
December 11, 2025 at 1:04 PM
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. ascopubs.org/doi/10.1200/...
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative #BreastCancer (RJBC 1501): A Randomized Phase III Trial. ascopubs.org/doi/10.1200/...
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial
PURPOSETo evaluate the efficacy and safety of adjuvant epirubicin plus cyclophosphamide followed
by taxanes (EC-T) versus EC-T plus carboplatin (EC-TCb) in patients with early-stage
triple-negative br...
ascopubs.org
December 11, 2025 at 1:03 PM
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative #BreastCancer (RJBC 1501): A Randomized Phase III Trial. ascopubs.org/doi/10.1200/...
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic #BreastCancer. ascopubs.org/doi/10.1200/...
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer
PurposeThe HER2CLIMB-05 study (ClinicalTrials.gov identifier: NCT05132582) is investigating the efficacy and safety of adding tucatinib to trastuzumab and
pertuzumab as first-line (1L) maintenance the...
ascopubs.org
December 11, 2025 at 1:00 PM
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic #BreastCancer. ascopubs.org/doi/10.1200/...
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. www.thelancet.com/journals/lan...
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
The addition of tafasitamab to lenalidomide and rituximab resulted in a statistically
significant and clinically meaningful improvement in progression-free survival, with
an acceptable safety profile ...
www.thelancet.com
December 11, 2025 at 12:35 PM
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. www.thelancet.com/journals/lan...
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. www.thelancet.com/journals/lan...
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
Epcoritamab plus R2 resulted in significantly higher response rate and longer progression-free
survival versus R2 among participants with follicular lymphoma who had received at
least one line of ther...
www.thelancet.com
December 11, 2025 at 12:33 PM
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. www.thelancet.com/journals/lan...
Image-guided intensity-modulated radiotherapy with reduced margins in patients with #ProstateCancer: Results of the RCMIGI randomized phase II trial. www.thegreenjournal.com/article/S016...
Image-guided intensity-modulated radiotherapy with reduced margins in patients with prostate cancer: Results of the RCMIGI randomized phase II trial
Prostate cancer is the most common cancer in men [1]. For localized prostate cancer,
treatments such as external beam radiotherapy (EBRT) and radical prostatectomy yield
similar outcomes [2,3]. Patien...
www.thegreenjournal.com
December 11, 2025 at 12:17 PM
Image-guided intensity-modulated radiotherapy with reduced margins in patients with #ProstateCancer: Results of the RCMIGI randomized phase II trial. www.thegreenjournal.com/article/S016...
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: Pooled analysis of 7 clinical trials performed in the first-line treatment of mCRC (German AIO Study Group). www.ejcancer.com/article/S095...
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trial...
Both BRAFV600E-mutation and right-sided primary tumor location (PTL), have been associated
with poor prognosis in metastatic colorectal cancer (mCRC). The present pooled analysis
of individual patient...
www.ejcancer.com
December 11, 2025 at 12:10 PM
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: Pooled analysis of 7 clinical trials performed in the first-line treatment of mCRC (German AIO Study Group). www.ejcancer.com/article/S095...
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell #LungCancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19). www.ejcancer.com/article/S095...
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – A multicenter single arm open...
Small cell lung cancer (SCLC) is an aggressive tumour type accounting for 10–15 %
of lung cancers. The role of thoracic radiotherapy (TRT) in extensive stage SCLC (ES_SCLC)
in the era of checkpoint in...
www.ejcancer.com
December 11, 2025 at 12:05 PM
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell #LungCancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19). www.ejcancer.com/article/S095...
Defining the clinical target volume (CTV) in post-operative Thymic Epithelial Tumours - A clinical practice guide for UK Clinical Oncologists. www.clinicaloncologyonline.net/article/S093...
Defining the clinical target volume (CTV) in post-operative Thymic Epithelial Tumours - A clinical practice guide for UK Clinical Oncologists.
Thymic epithelial tumours (TETs) are rare tumours, and most patients undergo curative
resection. A minority require post-operative radiotherapy, however current published
guidelines provide differing ...
www.clinicaloncologyonline.net
December 11, 2025 at 11:56 AM
Defining the clinical target volume (CTV) in post-operative Thymic Epithelial Tumours - A clinical practice guide for UK Clinical Oncologists. www.clinicaloncologyonline.net/article/S093...
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial. www.thelancet.com/journals/lan...
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
Vorasidenib reduced tumour growth rate and improved seizure control compared with
placebo, with no observed negative effects on HRQOL or neurocognition. Additional
follow-up supported the robustness o...
www.thelancet.com
December 11, 2025 at 11:51 AM
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial. www.thelancet.com/journals/lan...
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. www.thelancet.com/journals/lan...
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Camrelizumab plus rivoceranib showed a statistically significant and clinically meaningful
benefit in progression-free survival and overall survival compared with sorafenib
for patients with unresecta...
www.thelancet.com
December 11, 2025 at 11:49 AM
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. www.thelancet.com/journals/lan...
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early #BreastCancer: a pooled analysis of GBG and AGO-B Study Group trials. www.thelancet.com/journals/lan...
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials
With adequate follow-up, distant disease-free survival is a robust surrogate endpoint
for predicting final overall survival outcomes in neoadjuvant RCTs for early breast
cancer in most contexts. Howev...
www.thelancet.com
December 11, 2025 at 11:47 AM
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early #BreastCancer: a pooled analysis of GBG and AGO-B Study Group trials. www.thelancet.com/journals/lan...
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative #BreastCancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial. www.thelancet.com/journals/lan...
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, ...
In this exploratory, long-term analysis, extended adjuvant metronomic capecitabine
provided durable disease-free survival benefit in early triple-negative breast cancer,
although the findings should b...
www.thelancet.com
December 11, 2025 at 11:44 AM
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative #BreastCancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial. www.thelancet.com/journals/lan...
Best audio accompaniment for putting up Christmas decs? Obviously, it's the new Immunobuddies! Episode 171: Clinical Application of the Microbiome with International Expert Professor Monty Pal City of Hope California. @velindrecc.bsky.social @rickyfrazer1.bsky.social open.spotify.com/episode/1QtM...
Episode 171: Clinical Application of the Microbiome with International Expert Professor Monty Pal City of Hope California
open.spotify.com
December 5, 2025 at 9:58 AM
Best audio accompaniment for putting up Christmas decs? Obviously, it's the new Immunobuddies! Episode 171: Clinical Application of the Microbiome with International Expert Professor Monty Pal City of Hope California. @velindrecc.bsky.social @rickyfrazer1.bsky.social open.spotify.com/episode/1QtM...
Radiotherapy for Oesophageal #Cancer in the United Kingdom: Patterns of Practice and Quality Indicators @velindrecc.bsky.social www.sciencedirect.com/science/arti...
Radiotherapy for Oesophageal Cancer in the United Kingdom: Patterns of Practice and Quality Indicators
There is limited guidance relating to the provision of radiotherapy for patients with oesophageal cancer. Given this, we sought to assess variation in…
www.sciencedirect.com
December 4, 2025 at 2:27 PM
Radiotherapy for Oesophageal #Cancer in the United Kingdom: Patterns of Practice and Quality Indicators @velindrecc.bsky.social www.sciencedirect.com/science/arti...
CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence for regulatory science and innovation in pharmacogenomics (CERSI-PGx). @velindrecc.bsky.social bpspubs.onlinelibrary.wiley.com/doi/10.1002/...
BPS Publications
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and per...
bpspubs.onlinelibrary.wiley.com
December 4, 2025 at 2:23 PM
CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence for regulatory science and innovation in pharmacogenomics (CERSI-PGx). @velindrecc.bsky.social bpspubs.onlinelibrary.wiley.com/doi/10.1002/...